Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment

New England Journal of Medicine · Published 2026-07-29 · DOI 10.1056/nejmoa2607973

Authors (25)

Jürgen K. Rockstroh, Moti N. Ramgopal, Adrian Curran Fàbregas, Malcolm Hedgcock, Kimberly A. Workowski, Sylvie Ronot-Bregigeon, Isabel Cassetti, Cynthia Brinson, Samir K. Gupta, Chien-Ching Hung, Mark O’Reilly, Jihad Slim, Hiroyuki Gatanaga, Peter Shalit, Shan-Yu Liu, Stephanie O. Klopfer, Fadi Shihadeh, Nidhi Patel, Reneé-Claude Mercier, Melissa Shaughnessy, Hadas Dvory-Sobol, Devi SenGupta, Cyril Llamoso, Martin S. Rhee, Chloe Orkin

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Rockstroh, J., Ramgopal, M., Fàbregas, A., et al. (2026). Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2607973

Related articles